Daniel G Guy1, Geoffrey L Uy2. 1. Division of Oncology, Washington University School of Medicine, 660 S. Euclid Ave, CB 8007, St. Louis, MO, 63110, USA. 2. Division of Oncology, Washington University School of Medicine, 660 S. Euclid Ave, CB 8007, St. Louis, MO, 63110, USA. guy@wustl.edu.
Abstract
PURPOSE OF REVIEW: Bispecific antibodies combine antigen recognition sites from two or more antibodies into a single construct allowing simultaneous binding to multiple targets. Bispecific antibodies exist which can redirect immune effector cells against acute myeloid leukemia (AML) targets. This review will highlight the progress to date and the challenges in developing bispecific antibodies for the treatment of AML. RECENT FINDINGS: Currently, a number of bispecific antibody formats including bispecific T cell engagers, dual affinity retargeting proteins, and tandem diabodies are in clinical development for AML. These antibodies target antigens present on AML blasts, including CD33, and the low affinity IL3 receptor, CD123. T cell redirecting bispecific antibodies in early phase clinical trials for AML include AG330, flotetuzumab, JNJ-63709178, and AMV564. Bispecific antibodies represent a promising immunotherapeutic approach for the treatment of cancer. The results of ongoing studies in AML will elucidate the potential for these agents in AML.
PURPOSE OF REVIEW: Bispecific antibodies combine antigen recognition sites from two or more antibodies into a single construct allowing simultaneous binding to multiple targets. Bispecific antibodies exist which can redirect immune effector cells against acute myeloid leukemia (AML) targets. This review will highlight the progress to date and the challenges in developing bispecific antibodies for the treatment of AML. RECENT FINDINGS:Currently, a number of bispecific antibody formats including bispecific T cell engagers, dual affinity retargeting proteins, and tandem diabodies are in clinical development for AML. These antibodies target antigens present on AML blasts, including CD33, and the low affinity IL3 receptor, CD123. T cell redirecting bispecific antibodies in early phase clinical trials for AML include AG330, flotetuzumab, JNJ-63709178, and AMV564. Bispecific antibodies represent a promising immunotherapeutic approach for the treatment of cancer. The results of ongoing studies in AML will elucidate the potential for these agents in AML.
Entities:
Keywords:
Acute myeloid leukemia; Bispecific T cell engager; Bispecific antibody; Dual affinity retargeting protein
Authors: W L Blalock; C Weinstein-Oppenheimer; F Chang; P E Hoyle; X Y Wang; P A Algate; R A Franklin; S M Oberhaus; L S Steelman; J A McCubrey Journal: Leukemia Date: 1999-08 Impact factor: 11.528
Authors: James N Kochenderfer; Mark E Dudley; Steven A Feldman; Wyndham H Wilson; David E Spaner; Irina Maric; Maryalice Stetler-Stevenson; Giao Q Phan; Marybeth S Hughes; Richard M Sherry; James C Yang; Udai S Kammula; Laura Devillier; Robert Carpenter; Debbie-Ann N Nathan; Richard A Morgan; Carolyn Laurencot; Steven A Rosenberg Journal: Blood Date: 2011-12-08 Impact factor: 22.113
Authors: C T Jordan; D Upchurch; S J Szilvassy; M L Guzman; D S Howard; A L Pettigrew; T Meyerrose; R Rossi; B Grimes; D A Rizzieri; S M Luger; G L Phillips Journal: Leukemia Date: 2000-10 Impact factor: 11.528
Authors: Aran F Labrijn; Joyce I Meesters; Bart E C G de Goeij; Ewald T J van den Bremer; Joost Neijssen; Muriel D van Kampen; Kristin Strumane; Sandra Verploegen; Amitava Kundu; Michael J Gramer; Patrick H C van Berkel; Jan G J van de Winkel; Janine Schuurman; Paul W H I Parren Journal: Proc Natl Acad Sci U S A Date: 2013-03-11 Impact factor: 11.205
Authors: Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens Journal: Sci Transl Med Date: 2014-02-19 Impact factor: 17.956
Authors: Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June Journal: N Engl J Med Date: 2013-03-25 Impact factor: 91.245
Authors: David T Teachey; Susan R Rheingold; Shannon L Maude; Gerhard Zugmaier; David M Barrett; Alix E Seif; Kim E Nichols; Erica K Suppa; Michael Kalos; Robert A Berg; Julie C Fitzgerald; Richard Aplenc; Lia Gore; Stephan A Grupp Journal: Blood Date: 2013-05-15 Impact factor: 22.113
Authors: Uwe Reusch; Kimberly H Harrington; Chelsea J Gudgeon; Ivica Fucek; Kristina Ellwanger; Michael Weichel; Stefan H J Knackmuss; Eugene A Zhukovsky; Judith A Fox; Lori A Kunkel; Jeanmarie Guenot; Roland B Walter Journal: Clin Cancer Res Date: 2016-05-17 Impact factor: 12.531
Authors: Annachiara Dozzo; Aoife Galvin; Jae-Won Shin; Santo Scalia; Caitriona M O'Driscoll; Katie B Ryan Journal: Drug Deliv Transl Res Date: 2022-08-05 Impact factor: 5.671
Authors: Pingyan Cheng; Xianghong Chen; Robert Dalton; Alexandra Calescibetta; Tina So; Danielle Gilvary; Grace Ward; Victoria Smith; Sterling Eckard; Judith A Fox; Jeanmarie Guenot; Joseph Markowitz; John L Cleveland; Kenneth L Wright; Alan F List; Sheng Wei; Erika A Eksioglu Journal: Mol Ther Date: 2022-02-09 Impact factor: 12.910
Authors: Jan P Bogen; Stefania C Carrara; David Fiebig; Julius Grzeschik; Björn Hock; Harald Kolmar Journal: Front Immunol Date: 2021-05-10 Impact factor: 7.561